As previously reported by the INRG consortium [19,27], the clinical markers of stage 4, age ≥ 18 months, MYCN amplification, diploidy, high levels of ferritin and LDH, the adrenals as the primary tumor site, metastasis to bone marrow, bone, distant lymph nodes, and the lungs, unfavorable histology, and high MKI correlated with poor OS and EFS in JNB-FU-2014-605. This evidence concerns the gene MYCN and neoplasm.